Lovastatin protects mithochondrial and renal function in kidney ischemia-reperfusion in rats

Tucci, Sílvio; Molina, C.; Cassini, Marcelo Ferreira; Leal, Daniel Mendes; Schineider, Cássio Antonio Botene; Martins, Antônio Carlos Pereira

doi:10.1590/s0102-86502012000700008

Cited by 4 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other studies, statin intervention has been several days before ischemia–reperfusion injury [26,27] but, in the present study, drug intervention was after renal ischemia. AKI is an unpredictable event, so the present study has more clinical relevance compared with previous studies.…”

Section: Discussionmentioning

confidence: 71%

Atorvastatin treatment attenuates renal injury in an experimental model of ischemia–reperfusion in rats

Lei

Tian

et al. 2014

BMC Nephrol

View full text Add to dashboard Cite

BackgroundRecent studies in animal models have shown that statins can protect against renal failure independent of their lipid-lowering actions, and there is also an association between statin use and improved renal function after suprarenal aortic clamping. We investigated the hypothesis that post-ischemic acute renal failure could be ameliorated with atorvastatin (ATO) treatment and the possible molecular mechanisms in a model of ischemia–reperfusion (IR) in rats.MethodsTwenty-four male Sprague–Dawley rats were divided into three groups: sham, IR, and IR + ATO. ATO was given by a single intraperitoneal injection (10 mg/kg) 30 min before reperfusion in the IR + ATO group. The IR group and sham group received saline vehicle via the intraperitoneal route.ResultsAfter 24 h of IR, serum creatinine levels were increased in the IR group compared with the sham group (p < 0.001). ATO treatment reduced the elevation of serum creatinine level by 18% (p < 0.05) and significantly increased the creatinine clearance rate (p < 0.001). Concentrations of advanced oxidation protein products and malondialdehyde were reduced in the ATO group, approaching levels observed in sham-group rats. ATO treatment alleviated pathological changes in renal tubular cells. Protein and mRNA levels of intercellular adhesion molecule-1 and monocyte chemotactic protein-1 were reduced significantly.ConclusionsThese data suggest that direct protection of injured kidneys by ATO was possible even though the drug was injected 30 min before reperfusion, and that ATO may reduce IR injury by anti-inflammatory effects and by reducing oxidation stress.

show abstract

Section: Discussionmentioning

confidence: 71%

Atorvastatin treatment attenuates renal injury in an experimental model of ischemia–reperfusion in rats

Lei

Tian

et al. 2014

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…Tucci Jr et al investigated the effects of lovastatin (15 mg/ kg per day) on renal ischemia, followed by reperfusion on 31 rats, and reported significantly lower mortality rates as well as serum urea and creatinine levels in the lovastatin group compared to the control cases without any treatment (14).…”

Section: Discussionmentioning

confidence: 99%

The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma?

Acar¹,

Gülpembe²,

Yıldız³

et al. 2017

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: We aim to determine the effects of low-dose atorvastatin treatment together with crush fluid resuscitation on renal functions and muscle enzyme levels in a rat model of crush syndrome. Materials and methods:The study involved female Wistar Albino rats weighing 250-300 g that were housed with free access to food and water. The crush model was obtained by compression. Rats were randomly divided into four groups: control (C) group, atorvastatin + crush fluid (ACF) group, crush fluid (CF) group, and hypertonic saline (%3) + mannitol + sodium bicarbonate (SM) group. Blood was obtained at 24, 48, and 72 h, and serum creatinine kinase, myoglobin, urea, creatinine, and lactate dehydrogenase levels were studied.Results: All parameters were statistically significantly higher in the control group than in the treatment groups at all hours. However, there was no statistically significant difference among treatment groups regarding any of the parameters. Conclusion:This is the first study determining the role of atorvastatin in the treatment of renal ischemia/reperfusion injury in a crush syndrome and rhabdomyolysis model setting. Larger studies with different atorvastatin doses are required to define the role of this drug in the treatment of renal ischemia/reperfusion injury during crush syndrome.

show abstract

Impact of High Loading Dose of Atorvastatin in Diabetic Patients with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial

Shehata

Hamza

2015

Cardiovascular Therapeutics

View full text Add to dashboard Cite

SUMMARYIntroduction: The effectiveness of statin pretreatment in reducing the incidence of contrast-induced nephropathy (CIN) has been examined in some observational and randomized studies, yielding controversial results. Aim: This study sought to evaluate the role of atorvastatin in prevention of CIN in diabetic patients with mild-to-moderate chronic kidney disease (CKD), undergoing elective percutaneous coronary intervention (PCI). Methods: 130 patients with mean glomerular filtration rate of 48.5 AE 16 mL/min/1.73 m were prospectively enrolled, then randomly (double blind) assigned in 1:1 ratio to receive atorvastatin (80 mg daily for 48 h) or placebo. Serum creatinine and glomerular filtration rate were measured preintervention, 72 h and 10 days thereafter. An increase in serum creatinine by >0.5 mg/dL (44.2 lmol/L) or >25% of baseline value was considered as CIN. Results: Mean age of the study cohort was 56 AE 5 years (males: 62%). Mean serum creatinine level in the placebo group increased significantly 3 days after coronary intervention and declined on the 10th day to a level that did not differ significantly from the baseline level, but still higher. However, in atorvastatin group, mean serum creatinine level showed a nonsignificant rise on the third day and then decreased to a level close to the baseline one, on the 10th day. Incidence of CIN was 7.7% in atorvastatin group and 20% in the placebo group (P < 0.05). Conclusion: Atorvastatin dose of 80 mg per day for 48 h is associated with decreased incidence of CIN in diabetic patients with CKD undergoing PCI.

show abstract

Lovastatin protects mithochondrial and renal function in kidney ischemia-reperfusion in rats

Cited by 4 publications

References 14 publications

Atorvastatin treatment attenuates renal injury in an experimental model of ischemia–reperfusion in rats

Atorvastatin treatment attenuates renal injury in an experimental model of ischemia–reperfusion in rats

The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma?

Impact of High Loading Dose of Atorvastatin in Diabetic Patients with Renal Dysfunction Undergoing Elective Percutaneous Coronary Intervention: A Randomized Controlled Trial

Contact Info

Product

Resources

About